- Home
- MCRB vs TSVT Comparison
MCRB vs TSVT Comparison
Compare MCRB & TSVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- TSVT
- Stock Information
- Founded
- MCRB 2010
- TSVT 2021
- Country
- MCRB United States
- TSVT United States
- Employees
- MCRB N/A
- TSVT N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- TSVT Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- TSVT Health Care
- Exchange
- MCRB Nasdaq
- TSVT Nasdaq
- Market Cap
- MCRB 141.9M
- TSVT 128.5M
- IPO Year
- MCRB 2015
- TSVT N/A
- Fundamental
- Price
- MCRB $0.80
- TSVT $2.61
- Analyst Decision
- MCRB Buy
- TSVT Buy
- Analyst Count
- MCRB 4
- TSVT 4
- Target Price
- MCRB $5.63
- TSVT $8.50
- AVG Volume (30 Days)
- MCRB 844.5K
- TSVT 272.3K
- Earning Date
- MCRB 03-04-2025
- TSVT 03-04-2025
- Dividend Yield
- MCRB N/A
- TSVT N/A
- EPS Growth
- MCRB N/A
- TSVT N/A
- EPS
- MCRB N/A
- TSVT N/A
- Revenue
- MCRB $126,325,000.00
- TSVT $45,620,000.00
- Revenue This Year
- MCRB N/A
- TSVT N/A
- Revenue Next Year
- MCRB N/A
- TSVT $37.70
- P/E Ratio
- MCRB N/A
- TSVT N/A
- Revenue Growth
- MCRB 12856.41
- TSVT N/A
- 52 Week Low
- MCRB $0.54
- TSVT $2.29
- 52 Week High
- MCRB $1.53
- TSVT $6.00
- Technical
- Relative Strength Index (RSI)
- MCRB 46.38
- TSVT 50.02
- Support Level
- MCRB $0.81
- TSVT $2.38
- Resistance Level
- MCRB $0.84
- TSVT $2.82
- Average True Range (ATR)
- MCRB 0.04
- TSVT 0.18
- MACD
- MCRB 0.00
- TSVT 0.04
- Stochastic Oscillator
- MCRB 45.58
- TSVT 58.18
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.